explore -WSS

explore

author：focus 2025-09-05 04:57:13 - browse：691

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

focus

Wikipedia

WSS

Living with Fabry disease, a condition that causes chronic pain

Criminal prosecution for violating HIPAA: an emerging threat

Criminal prosecution for violating HIPAA: an emerging threat

Second House panel advances two

Leqembi, other new Alzheimer’s drugs require better biomarkers

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

focus

explore

focus

The cancer drug shortage isn’t new — and neither are the solutions

Palantir health business leans on meeting customers’ needs

Hepatitis C has a cure — but many Americans still lack access to it

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

What does generative AI mean for health care? We asked experts

HCA discloses massive data breach affecting 11 million patients

Novavax promises a turnaround & Lilly roils the obesity market

Military medical care influenced by rank and race, new study finds

How to save PrEP access — and even expand it

Readers respond to H5N1 and livestock movements, and more

leisure time

Criminal prosecution for violating HIPAA: an emerging threat

HCA discloses massive data breach affecting 11 million patients

Iowa House, Senate pass 6

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Elizabeth Holmes on track for early release from her 11

Military medical care influenced by rank and race, new study finds

knowledge

focus

Wikipedia

hotspot